Treatment
Cell clinical trials
We’re tracking 5,682 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06481735RecruitingPhase 1/Phase 2
Modified donor CAR-T for B-cell leukemia
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
Beijing, Beijing MunicipalityAges 16–70 - NCT06481813Recruiting
Lung Cancer Biobank Study for Newly Diagnosed Patients
This trial collects blood and tissue samples from people newly diagnosed with lung cancer (NSCLC or CPC) to study the disease over time. It helps researchers understand how different treatments affect the cancer and the body.
NantesAges 18 years+ - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06484556RecruitingPhase 1
T cell therapy for KRAS-mutated advanced solid tumors
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Wuhan, HubeiAges 18–75 - NCT06484790RecruitingPhase 1
Engineered T cell therapy for KRAS-mutated advanced solid tumors
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06485076Recruiting
Early comfort care for multiple myeloma and aggressive lymphoma
This study offers a palliative care team (doctors and nurses focused on comfort and quality of life) to people newly diagnosed with multiple myeloma or with an aggressive lymphoma that has come back. The goal is to help manage symptoms early, so you feel better and stay stronger during your cancer treatment.
Toronto, OntarioAges 18 years+ - NCT06485778RecruitingPhase 2
Radiation after surgery for early-stage oral tongue cancer
This trial tests whether giving radiation after surgery can lower the risk of the cancer coming back for people with oral tongue cancer that has specific high-risk features but not advanced spread. It aims to find the best treatment plan for patients with certain tumor characteristics.
Basking Ridge, New JerseyAges 18 years+ - NCT05027945RecruitingPhase 2
Stem cell transplant for people with VEXAS syndrome
This Phase 2 trial tests whether an allogeneic stem cell transplant (from a donor) can treat VEXAS syndrome. It may help calm the body’s overactive inflammation and improve symptoms in eligible adults.
Bethesda, MarylandAges 18–75 - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Gilbert, ArizonaAges 18 years+ - NCT07692152RecruitingPhase 3
Immunotherapy vs. chemo for MS anal cancer trial
This trial tests sintilimab (a type of immunotherapy) against mitomycin plus chemotherapy with radiation for anal cancer that hasn't spread. It aims to find a better treatment with fewer side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+ - NCT07155187RecruitingPhase 2/Phase 3
Study of telisotuzumab adizutecan for EGFR-mutated lung cancer
This trial tests a new drug, telisotuzumab adizutecan (given through a vein), alone or with another targeted therapy, versus standard treatments for people with a specific type of advanced lung cancer that has an EGFR mutation and has gotten worse after previous treatment.
Springdale, ArkansasAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT07586124RecruitingPhase 2
Immunotherapy plus antibody drug for advanced head and neck cancer
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06488898RecruitingPhase 2
Cell therapy to stabilize large abdominal aortic aneurysm
This trial tests whether a special cell treatment can help stabilize a large abdominal aortic aneurysm (AAA) instead of just watching it grow. You may qualify if your aneurysm is at least 5 cm wide and you are scheduled for standard endovascular repair.
MadridAges 18 years+ - NCT06492460RecruitingPhase 3
Two courses of chemo-radiation after surgery for high-risk head and neck cancer
This trial tests whether giving two rounds of cisplatin chemo along with radiation after surgery can help people with high-risk head and neck squamous cell carcinoma. It is for patients who have already had surgery and whose cancer showed signs of being more aggressive.
Guangzhou, GuangdongAges 18–70 - NCT06492798RecruitingPhase 1/Phase 2
Stem cells for Long COVID: a safety and effectiveness study
This study tests whether a single infusion of mesenchymal stem cells can help with Long COVID symptoms—without causing serious side effects. It’s for people who are still struggling with COVID-related health problems months after their initial infection.
ShanghaiAges 18–70 - NCT06496490RecruitingPhase 2
TQB2102 for HER2-mutated non-small cell lung cancer
This trial tests a new drug, TQB2102, for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene and has stopped responding to standard treatments. It aims to see if the drug can shrink or slow the cancer.
Fuzhou, FujianAges 18–75 - NCT06497452Recruiting
Glofitamab with rescue therapy for relapsed B-cell lymphoma
This study is testing how well the drug Glofitamab works when given along with standard rescue treatments for adults with B-cell Non-Hodgkin Lymphoma that has relapsed or not responded to prior therapy. The goal is to see if this combination is effective and safe in everyday medical practice.
Suzhou, JiangsuAges 18 years+ - NCT06498479RecruitingPhase 3
Comparing a new drug to topotecan for relapsed small cell lung cancer
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06498986RecruitingPhase 2
BL-B01D1 plus osimertinib for EGFR-mutant lung cancer
This trial tests a new drug (BL-B01D1) combined with osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and who have not had any previous treatment. The goal is to see if the combination works better than standard care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06500728Recruiting
Vision involvement in giant cell arteritis
This study looks at how vision is affected in people with giant cell arteritis (GCA) -- a condition where blood vessels become inflamed. It compares those with GCA-related vision loss to people who have similar vision problems but not from GCA, to better understand and treat these eye issues.
Milan, LombardyAges 18 years+ - NCT06503107RecruitingPhase 1/Phase 2
Nanobody-based CAR-T cells for multiple myeloma
This trial tests a new type of CAR-T cell therapy that targets a protein called BCMA on your myeloma cells. It is for people with multiple myeloma that has not responded to or has come back after several prior treatments.
Wuhan, HubeiAges 18–75
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,682 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.